<DOC>
	<DOCNO>NCT01629511</DOCNO>
	<brief_summary>The goal clinical research study learn high tolerable dose gemcitabine ( 4 possible dos ) give combination busulfan clofarabine allogeneic stem cell transplant . Researchers also want learn combination help control CLL . The safety treatment also study . Busulfan design bind DNA ( genetic material cell ) , may cause cancer cell die . It commonly use stem cell transplant . Clofarabine gemcitabine design block growth cancer cell , may cause cancer cell die .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Study Drug Administration : On day Day -15 -8 ( 15 8 day receive stem cell transplant ) , receive low-level `` test '' dose busulfan vein 1 hour . You may receive test dose Day -8 outpatient clinic , Day -8 inpatient hospital . Blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test 11 time 11 hour busulfan dose test dose . PK test measure amount study drug body different time point , case use figure dose busulfan . The study staff tell PK test schedule . The PK test help doctor decide dose busulfan Days -6 -3 . A heparin lock line place vein PK test begin low number needle stick need draws . If reason possible PK test perform , receive standard dose busulfan . On Day -9 Day -7 , admit hospital give fluid vein hydrate . On Days -6 -4 , receive gemcitabine vein 10-25 minute . The dose receive base join study . Up 4 dose level gemcitabine test . Up 3 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose gemcitabine find . Once high dose find , additional participant enrol dose . The number patient group depend many enrolled group . Each day Days -6 Day -3 , receive clofarabine vein 1 hour follow body-specific dose busulfan vein 3 hour . If reason could PK test perform , receive standard busulfan dose day . On Day -3 Day -1 , stem cell donor relate , receive antithymocyte globulin ( ATG ) vein 4 hour day . ATG design weaken immune system order low risk body reject transplant . Beginning Day -2 , receive tacrolimus 24 hour every day able take mouth . Tacrolimus design weaken immune system low risk graft-versus-host-disease ( GVHD - reaction donor 's immune cell body ) . Once able take tacrolimus mouth , take every day 6 month , doctor think safe stop taking . On Day 0 , receive donor 's stem cell vein . The infusion last anywhere 30 minute several hour . On Days 1 , 3 , 6 , 11 , receive methotrexate vein 15 minute . Methotrexate also design weaken immune system low risk GVHD . Starting 1 week transplant , receive filgrastim ( G-CSF ) injection skin 1 time day blood cell level return normal . You may give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : On day Day -15 Day -8 , Day -5 Day -3 ( busulfan test dose , day first second dose gemcitabine , total 3 time ) , blood ( 2 teaspoon ) drawn test check effect study drug DNA ( genetic material ) blood cell . About 4 week transplant : - You physical exam , include measurement vital sign ( blood pressure , temperature , heart rate , breathe rate ) . - You ask feel side effect may . - You check possible reaction study treatment , include GVHD . - Blood ( 4 tablespoon ) draw routine test , see transplant take , check status disease . Length Treatment : You study 2 year . You take study early graft failure ( transplant `` take '' ) , disease come back need another treatment , follow study direction , study doctor think best interest , want leave study . You must talk study doctor want leave study early . It may life-threatening leave study begin receive study drug receive stem cell , blood cell count dangerously low . Follow-Up : About 3 , 6 , 12 month transplant , every 6 month 1 year : - You physical exam . - You ask feel side effect may . - You check possible reaction treatment , include GVHD . - Blood ( 4 tablespoon ) draw routine test , see well transplant take , check status disease . - At point doctor think need , bone marrow aspiration compute tomography ( CT ) scan check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . The study staff also stay contact local doctor find disease come back check . This investigational study . Gemcitabine clofarabine FDA approve commercially available treatment leukemia . Busulfan FDA approve commercially available use stem cell transplantation . It investigational test best dose gemcitabine give busulfan clofarabine help prevent disease come back . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age 18 70 year age . 2 . Patients chronic lymphocytic leukemia , prolymphocytic leukemia , Richter 's transformation eligible allogeneic transplantation eligible protocol high priority . 3 . A 10/10 HLA match ( high resolution type A , B , C , DRB1 , DQ1 ) sibling unrelated donor . 4 . Left ventricular EF &gt; 40 % . 5 . FEV1 , FVC correct DLCO &gt; 40 % . 6 . Serum creatinine &lt; 1.6 mg/dL . Serum bilirubin &lt; 2X upper limit normal . 7 . SGPT &lt; 2X upper limit normal . 8 . Voluntary sign , write IRBapproved informed consent . 9 . Men woman reproductive potential must agree follow accepted birth control method duration study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . 1 . Patient active CNS disease . 2 . Pregnant ( Positive Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization ) currently breastfeed . Pregnancy test require postmenopausal surgically sterilize woman . 3 . Known infection HIV , HTLVI , Hepatitis B , Hepatitis C. 4 . Active uncontrolled bacterial , viral fungal infection . 5 . Patient receive investigational drug within 1 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Allogeneic hematopoietic cell transplantation</keyword>
	<keyword>HCT</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
</DOC>